IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer is a paper indexed in PICO Portal from OpenAlex.
How many citations does IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer have?
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer has 548 citations in the OpenAlex counts PICO Portal stores.
When was IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer published?
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer has 2016 year in the PICO Portal index.
What is the open-access status of IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer?
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer has bronze oa status in the PICO Portal index.
What is the DOI of IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer?
The DOI for IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer is on the source record.
What is the PMID of IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer?
The PMID for IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer is on the source record.
What is the OpenAlex record for IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer?
The OpenAlex for IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer is on the source record.